Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 6865-6878

  Narsireddy, Amreddy ^a   Vijayashree, Kurra ^b   Adimoolam, Mahesh G ^a   Manorama, Sunkara V ^a   Rao, Nalam M ^b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

Affibody; Dendrimers; Nanoparticle; Photodynamic therapy; Targeted delivery; Xenograft animal model

Indexed keywords

5,10,15,20 TETRAKIS(4 HYDROXYPHENYL) 21H,23H PORPHINE; DENDRIMER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; NITRILOTRIACETIC ACID; PHOTOSENSITIZING AGENT; POLYAMIDOAMINE; UNCLASSIFIED DRUG; 1,3-DIPHENYLISOBENZOFURAN; BENZOFURAN DERIVATIVE; PAMAM STARBURST; PEPTIDE; SINGLET OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER INHIBITION; CELL DEATH; CELL TRANSPORT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; EXPRESSION VECTOR; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; METABOLISM; NUDE MOUSE; PHOTOCHEMOTHERAPY; PROCEDURES; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROFLUOROMETRY; STATIC ELECTRICITY; TUMOR CELL LINE; ULTRAVIOLET SPECTROPHOTOMETRY;

ANIMALS; BENZOFURANS; CELL LINE, TUMOR; DENDRIMERS; HUMANS; MICE, NUDE; PEPTIDES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROTON MAGNETIC RESONANCE SPECTROSCOPY; SINGLET OXYGEN; SPECTROMETRY, FLUORESCENCE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; STATIC ELECTRICITY;

EID: 84946867392     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S89474     Document Type: Review

References (58)

1. Triesscheijn M, Baas P, Schellens JH, Stewart FA. Photodynamic therapy in oncology. Oncologist. 2006;11:1034-1044.
2. Celli JP, Spring BQ, Rizvi I, et al. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization. Chem Rev. 2010;110:2795-2838.
3. Kruft BI, Greer A. Photosensitization reactions in vitro and in vivo. Photochem Photobiol. 2011;87:1204-1213.
4. Chen B, Pogue BW, Hoopes PJ, Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr. 2006;16:279-305.
5. Shirasu N, Nam SO, Kuroki M. Tumor-targeted photodynamic therapy. Anticancer Res. 2013;33:2823-2831.
6. Klajnert B, Rozanek M, Bryszewska M. Dendrimers in photodynamic therapy. Curr Med Chem. 2012;19:4903-4912.
7. Schmitt F, Juillerat-Jeanneret L. Drug targeting strategies for photodynamic therapy. Anticancer Agents Med Chem. 2012;12:500-525.
8. ® for palliative treatment of late-stage lung cancer. J Clin Laser Med Surgery. 1998;16:334.
9. Bai D, Xia X, Yow CM, Chu ES, Xu C. Hypocrellin B-encapsulated nanoparticle-mediated rev-caspase-3 gene transfection and photodynamic therapy on tumor cells. Eur J Pharmacol. 2011;650: 496-500.
10. Goff BA, Blake J, Bamberg MP, Hasan T. Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. Br J Cancer. 1996;74:1194-1198.
11. Bugaj AM. Targeted photodynamic therapy - a promising strategy of tumor treatment. Photochem Photobiol Sci. 2011;10:1097-1109.
12. Majoros IJ, Williams CR, Baker JR Jr. Current dendrimer applications in cancer diagnosis and therapy. Curr Top Med Chem. 2008;8:1165-1179.
13. Baker JR Jr. Dendrimer-based nanoparticles for cancer therapy. Hematology Am Soc Hematol Educ Program. 2009;708-719.
14. Liu J, Gray WD, Davis ME, Luo Y. Peptide- and saccharide-conjugated dendrimers for targeted drug delivery: a concise review. Interface Focus. 2012;2:307-324.
15. Chen HT, Neerman MF, Parrish AR, Simanek EE. Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J Am Chem Soc. 2004;126:10044-10048.
16. Daftarian P, Kaifer AE, Li W, et al. Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. Cancer Res. 2011;71:7452-7462.
17. Kobayashi H, Sato N, Hiraga A, et al. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn Reson Med. 2001;45:454-460.
18. Duan X, Sheardown H. Dendrimer crosslinked collagen as a corneal tissue engineering scaffold: mechanical properties and corneal epithelial cell interactions. Biomaterials. 2006;27:4608-4617.
19. Zhang GD, Harada A, Nishiyama N, et al. Polyion complex micelles entrapping cationic dendrimer porphyrin: effective photosensitizer for photodynamic therapy of cancer. J Control Release. 2003;93:141-150.
20. Battah SH, Chee CE, Nakanishi H, Gerscher S, MacRobert AJ, Edwards C. Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy. Bioconjug Chem. 2001;12:980-988.
21. Li WS, Aida T. Dendrimer porphyrins and phthalocyanines. Chem Rev. 2009;109:6047-6076.
22. Battah S, Balaratnam S, Casas A, et al. Macromolecular delivery of 5-aminolaevulinic acid for photodynamic therapy using dendrimer conjugates. Mol Cancer Ther. 2007;6:876-885.
23. Cheng Y, Samia C, Meyers JD, Panagopoulos I, Fei B, Burda C. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer. J Am Chem Soc. 2008;130:10643-10647.
24. Roby A, Erdogan S, Torchilin VP. Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. Cancer Biol Ther. 2007;6:1136-1142.
25. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198.
26. Jardines L, Weiss M, Fowble B, Greene M. neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology. 1993;61:268-282.
27. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16-32.
28. Howe LR, Brown PH. Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila). 2011;4:1149-1157.
29. Feldwisch J, Tolmachev V. Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol. 2012;899:103-126.
30. Lofblom J, Feldwisch J, Tolmachev V, Carlsson J, Stahl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010;584:2670-2680.
31. Tolmachev V, Orlova A, Nilsson FY, Feldwisch J, Wennborg A, Abrahmsen L. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther. 2007;7:555-568.
32. Loughran ST, Loughran NB, Ryan BJ, D'Souza BN, Walls D. Modified His-tag fusion vector for enhanced protein purification by immobilized metal affinity chromatography. Anal Biochem. 2006;355:148-150.
33. Wozniak M, Tanfani F, Bertoli E, Zolese G, Antosiewicz J. A new fluorescence method to detect singlet oxygen inside phospholipid model membranes. Biochim. et Biophys Acta. 1991;1082:94-100.
34. Govindarajan S, Sivakumar J, Garimidi P, et al. Targeting human epidermal growth factor receptor 2 by a cell-penetrating peptide-affibody bioconjugate. Biomaterials. 2012;33:2570-2582.
35. Wu B, Kerkeni B, Egami T, et al. Structured water in polyelectrolyte dendrimers: understanding small angle neutron scattering results through atomistic simulation. J Chem Phys. 2012;136:144901.
36. Uehara T, Ishii D, Uemura T, et al. gamma-Glutamyl PAMAM dendrimer as versatile precursor for dendrimer-based targeting devices. Bioconjug Chem. 2010;21:175-181.
37. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008;83:761-769.
38. Gajbhiye V, Palanirajan VK, Tekade RK, Jain NK. Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol. 2009;61:989-1003.
39. Huang Z. A review of progress in clinical photodynamic therapy. Technol Cancer Res Treat. 2005;4:283-293.
40. Phillips D. Toward targeted photodynamic therapy. Pure Appl Chem. 2011;83:733-748.
41. Kaminskas LM, McLeod VM, Kelly BD, et al. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine. 2012;8:103-111.
42. Lai PS, Lou PJ, Peng CL, et al. Doxorubicin delivery by polyamidoamine dendrimer conjugation and photochemical internalization for cancer therapy. J Control Release. 2007;122:39-46.
43. Yin Z, Liu N, Ma M, Wang L, Hao Y, Zhang X. A novel EGFR-targeted gene delivery system based on complexes self-assembled by EGF, DNA, and activated PAMAM dendrimers. Int J Nanomedicine. 2012;7:4625-4635.
44. Khdair A, Handa H, Mao G, Panyam J. Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance in vitro. Eur J Pharm Biopharm. 2009;71:214-222.
45. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63:136-151.
46. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem. 2007;101:937-949.
47. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653-664.
48. Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem. 2012;19:3794-3804.
49. Pearce TR, Shroff K, Kokkoli E. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv Mater. 2012;24:3803-3822, 3710.
50. MacEwan SR, Chilkoti A. Harnessing the power of cell-penetrating peptides: activatable carriers for targeting systemic delivery of cancer therapeutics and imaging agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013;5:31-48.
51. Miyano T, Wijagkanalan W, Kawakami S, Yamashita F, Hashida M. Anionic amino acid dendrimer-trastuzumab conjugates for specific internalization in HER2-positive cancer cells. Mol Pharm. 2010;7:1318-1327.
52. Master AM, Qi Y, Oleinick NL, Gupta AS. EGFR-mediated intracellular delivery of Pc 4 nanoformulation for targeted photodynamic therapy of cancer: in vitro studies. Nanomedicine. 2012;8:655-664.
53. Nishiyama N, Stapert HR, Zhang GD, et al. Light-harvesting ionic dendrimer porphyrins as new photosensitizers for photodynamic therapy. Bioconjug Chem. 2003;14:58-66.
54. Remant BK, Chandrashekaran V, Cheng B, et al. Redox potential ultrasensitive nanoparticle for the targeted delivery of camptothecin to HER2-positive cancer cells. Mol Pharm. 2014;11:1897-1905.
55. Gao J, Chen K, Miao Z, et al. Affibody-based nanoprobes for HER2-expressing cell and tumor imaging. Biomaterials. 2011;32:2141-2148.
56. Narsireddy A, Vijayashree K, Irudayaraj J, Manorama SV, Rao NM. Targeted in vivo photodynamic therapy with epidermal growth factor receptor-specific peptide linked nanoparticles. Int J Pharm. 2014;471:421-429.
57. 4-Au nanoparticles for biomedical applications. Chempluschem. 2012;77:284-292.
58. Galeazzi S, Hermans TM, Paolino M, et al. Multivalent supramolecular dendrimer-based drugs. Biomacromolecules. 2010;11:182-186.